本文關(guān)鍵詞：表柔比星注射液聯(lián)合順鉑注射液治療晚期耐藥性子宮內(nèi)膜癌的臨床研究　出處：《中國臨床藥理學(xué)雜志》2017年05期 　論文類型：期刊論文

  更多相關(guān)文章： 表柔比星注射液 順鉑注射液 晚期耐藥性子宮內(nèi)膜癌 安全性

【摘要】：目的觀察表柔比星注射液聯(lián)合順鉑注射液治療晚期耐藥性子宮內(nèi)膜癌的臨床療效及安全性。方法將56例晚期耐藥性子宮內(nèi)膜癌患者隨機(jī)分為對照組28例與試驗組28例。對照組予以順鉑30 mg·m-2,第1,8天,靜脈滴注+氟尿嘧啶650 mg·m-2,第1,8天,靜脈滴注;試驗組予以順鉑30 mg·m-2,第1,8天,靜脈滴注+表柔比星40 mg·m-2,第1天,靜脈滴注。2組患者一個療程均為4周,共治療2個療程。比較2組患者的臨床療效、卵巢癌抗原(CA125)、附睪蛋白4(HE4)、脂聯(lián)素(APN)以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗組和對照組的總有效率分別為85.71%(24/28例)和60.71%(17/28例),差異有統(tǒng)計學(xué)意義(P0.05)。治療后,試驗組和對照組的CA125分別為(28.62±0.33),(40.52±0.45)U·L~(-1);HE4分別為(1.57±0.24),(35.93±0.38)pmol·L~(-1);APN分別為(8.59±0.98),(7.74±0.78)μg·m L~(-1),差異均有統(tǒng)計學(xué)意義(P0.05)。試驗組的藥物不良反應(yīng)主要有脫發(fā)、口腔黏膜炎、惡心嘔吐、腹瀉和白細(xì)胞減少,對照組的藥物不良反應(yīng)主要有脫發(fā)、食欲缺乏、惡心嘔吐、白細(xì)胞減少、血小板減少和蛋白尿。試驗組和對照組的藥物不良反應(yīng)發(fā)生率分別為21.43%和32.14%,差異無統(tǒng)計學(xué)意義(P0.05)。結(jié)論表柔比星注射液聯(lián)合順鉑注射液治療晚期耐藥性子宮內(nèi)膜癌的臨床療效顯著,且不增加藥物不良反應(yīng)的發(fā)生率。
[Abstract]:Objective to observe the clinical efficacy and safety of epirubicin injection combined with cisplatin injection in the treatment of advanced drug-resistant endometrial carcinoma. Methods 56 patients with advanced drug-resistant endometrial carcinoma were randomly divided into control group (n = 28) and trial group (n = 28). The control group was treated with cisplatin 30. Mg 路m-2. On the 1st day, 650mg 路m -2 fluorouracil was injected intravenously, and on the 1st day, 650mg 路m -2 was injected intravenously. The experimental group was given cisplatin 30 mg 路m ~ (-2), day 1 8, epirubicin 40 mg 路m ~ (-2). On day 1, the course of treatment in group 2 was 4 weeks. To compare the clinical efficacy of the two groups, ovarian cancer antigen CA125, epididymal protein 4 (HE4). Adiponectin (APN) and adverse drug reactions. Results after treatment. The total effective rates of the test group and the control group were 85.71 / 24 / 28 and 60.71 / 17 / 28, respectively. The difference was statistically significant (P 0.05). The CA125 of the experimental group and the control group were 40.52 鹵0.45 U 路L ~ (-1) and 28.62 鹵0.33 U 路L ~ (-1), respectively. HE4 was 1.57 鹵0.24, respectively. The HE4 was 35.93 鹵0.38 pmol 路L ~ (-1). APN was 8.59 鹵0.98 渭 g 路mL ~ (-1), respectively (7.74 鹵0.78) 渭 g 路mL ~ (-1). The main adverse drug reactions in the test group were alopecia, oral mucositis, nausea and vomiting, diarrhea and leukopenia, while the adverse drug reactions in the control group were alopecia. Appetite deficiency, nausea and vomiting, leukopenia, thrombocytopenia and proteinuria. The incidence of adverse drug reactions in the trial group and control group was 21.43% and 32.14%, respectively. Conclusion the clinical efficacy of epirubicin injection combined with cisplatin injection in the treatment of advanced drug-resistant endometrial carcinoma is significant and the incidence of adverse drug reactions is not increased.
【作者單位】： 浙江大學(xué)醫(yī)學(xué)院附屬婦產(chǎn)科醫(yī)院婦產(chǎn)科;衢州市人民醫(yī)院婦產(chǎn)科;
【基金】：浙江省醫(yī)藥衛(wèi)生計劃基金資助項目(2011ZDA015)
【分類號】：R737.33
【正文快照】： (1.浙江大學(xué)醫(yī)學(xué)院附屬婦產(chǎn)科醫(yī)院婦產(chǎn)科,杭州310000;2.衢州市人民醫(yī)院婦產(chǎn)科,浙江衢州324300)FAN Su-hong1,2,LIN Jun1,MA Jun-yan1(1.Department of Gynecology,TheAffiliated Obstetrics and GynecologyHospital of Zhejiang University MedicalCollege,Hangzhou 310000,Ch

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王建,黃宗玉;高效毛細(xì)管電泳法測定鹽酸表柔比星的含量[J];藥物分析雜志;2000年06期

2 李春元;順鉑、表柔比星和絲裂霉素C對子宮頸玻璃樣細(xì)胞癌的療效[J];國外醫(yī)學(xué).藥學(xué)分冊;2000年06期

3 何劍英;;表柔比星與多柔比星治療老年非霍奇金淋巴瘤對比觀察[J];山西職工醫(yī)學(xué)院學(xué)報;2005年04期

4 劉紹璞;王芬;劉忠芳;胡小莉;;鹽酸表柔比星與核酸相互作用的共振瑞利散射光譜研究及其分析應(yīng)用[J];化學(xué)學(xué)報;2007年10期

5 屈強(qiáng);;惡性腫瘤患者表柔比星化療后心電圖異常情況[J];腫瘤基礎(chǔ)與臨床;2012年02期

6 屈強(qiáng);;參附注射液對表柔比星化療患者心臟毒性的影響[J];腫瘤基礎(chǔ)與臨床;2012年03期

7 王秋生;樓尉;陳駿萍;葛w搛，

本文編號：1420505